Literature DB >> 34150138

LNG-IUS combined with progesterone ameliorates endometrial thickness and pregnancy outcomes of patients with early-stage endometrial cancer or atypical hyperplasia.

Fang Fang1, Hao Xu2, Ling Wu1, Linyi Hu1, Ying Liu1, Yinnan Li1, Chunhua Zhang1.   

Abstract

OBJECTIVE: To determine the positive effect of levonorgestrel-releasing intrauterine system (LNG-IUS) combined with progesterone on endometrial thickness and pregnancy outcomes of patients with atypical endometrial hyperplasia (AEH) or early-stage endometrial cancer (EEC).
METHODS: Patients with AEH or EEC admitted to our hospital were enrolled, and assigned to a control group (con group) and a combination group (com group). Patients in the con group were treated with LNG-IUS, while those in the com group were treated with LNG-IUS combined with progesterone. After treatment, the two groups were compared in efficacy, menstrual blood volume (pictorial blood loss assessment chart (PBAC) score), and changes in endometrial thickness. In addition, the incidence of adverse drug reactions and pregnancy outcomes of the patients were analyzed.
RESULTS: Before treatment, there was no significant difference in PBAC score and endometrial thickness between patients with AEH or EEC in the con group and those in the com group, but after 3 months and 6 months of treatment, the com group got a better PBAC score and better changes of endometrial thickness than the con group, and the incidence of adverse drug reactions in the com group was also significantly lower than that in the con group. In addition, the follow-up results of pregnancy outcomes of patients showed that the fertility rate and total effective rate of the com group were both significantly higher than those of the con group (both P<0.05).
CONCLUSION: LNG-IUS combined with progesterone is more effective in treating patients with AEH or EEC. It can effectively improve the endometrial thickness of patients and fertility rate of those with fertility requirements after treatment. AJTR
Copyright © 2021.

Entities:  

Keywords:  Levonorgestrel-releasing intrauterine system; atypical endometrial hyperplasia; early-stage endometrial cancer; endometrial thickness; pregnancy outcome; progesterone

Year:  2021        PMID: 34150138      PMCID: PMC8205653     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  27 in total

1.  Effects of a Levonorgestrel-Releasing Intrauterine System on the Expression of Steroid Receptor Coregulators in Adenomyosis.

Authors:  Bo Hyon Yun; Young Eun Jeon; Seok Kyo Seo; Joo Hyun Park; Sun Och Yoon; SiHyun Cho; Young Sik Choi; Byung Seok Lee
Journal:  Reprod Sci       Date:  2015-06-02       Impact factor: 3.060

2.  Progesterone.

Authors:  James H Pickar
Journal:  Climacteric       Date:  2018-08       Impact factor: 3.005

3.  Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.

Authors:  Bingyi Yang; Yuhui Xu; Qin Zhu; Liying Xie; Weiwei Shan; Chengcheng Ning; Bingying Xie; Yue Shi; Xuezhen Luo; Hongwei Zhang; Xiaojun Chen
Journal:  Gynecol Oncol       Date:  2019-01-21       Impact factor: 5.482

4.  IMMUNOHISTOCHEMISTRY IN ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL ADENOCARCINOMA.

Authors:  Demetra Socolov; R Socolov; Ivona Aughelache Lupascu; V Rugina; O Gabia; Daniela Mihaela Garauleanu; A Carauleanu
Journal:  Rev Med Chir Soc Med Nat Iasi       Date:  2016 Apr-Jun

5.  Effects of estrogen and progesterone administration on extracellular fluid.

Authors:  Nina S Stachenfeld; Hugh S Taylor
Journal:  J Appl Physiol (1985)       Date:  2003-12-05

6.  Fertility outcomes in infertile women with complex hyperplasia or complex atypical hyperplasia who received progestin therapy and in vitro fertilization.

Authors:  Miao Li; Jia-Lun Song; Ying Zhao; She-Ling Wu; Hong-Bin Liu; Rong Tang; Lei Yan
Journal:  J Zhejiang Univ Sci B       Date:  2017 Nov.       Impact factor: 3.066

7.  Endometrial polyps: when to resect?

Authors:  Julia Marques da Rocha de Azevedo; Ligia Marques da Rocha de Azevedo; Fernando Freitas; Maria Celeste Osorio Wender
Journal:  Arch Gynecol Obstet       Date:  2015-08-25       Impact factor: 2.344

8.  Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?

Authors:  Wataru Yamagami; Nobuyuki Susumu; Takeshi Makabe; Kensuke Sakai; Hiroyuki Nomura; Fumio Kataoka; Akira Hirasawa; Kouji Banno; Daisuke Aoki
Journal:  J Gynecol Oncol       Date:  2018-01-02       Impact factor: 4.401

9.  Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study.

Authors:  Umberto Leone Roberti Maggiore; Fabio Martinelli; Giulia Dondi; Giorgio Bogani; Valentina Chiappa; Maria Teresa Evangelista; Viola Liberale; Antonino Ditto; Simone Ferrero; Francesco Raspagliesi
Journal:  J Gynecol Oncol       Date:  2019-02-26       Impact factor: 4.401

Review 10.  The role of levonorgestrel intrauterine systems in the treatment of symptomatic fibroids.

Authors:  Wojciech Wrona; Anna Stępniak; Piotr Czuczwar
Journal:  Prz Menopauzalny       Date:  2017-12-30
View more
  1 in total

Review 1.  Contraception During Perimenopause: Practical Guidance.

Authors:  Giovanni Grandi; Pierluigi Di Vinci; Alice Sgandurra; Lia Feliciello; Francesca Monari; Fabio Facchinetti
Journal:  Int J Womens Health       Date:  2022-07-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.